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OBJECTIVES: To examine the natural course of depressive
symptoms in patients with probable Alzheimer’s disease
(AD), specifically, the temporal relationship between de-
pressive symptoms, function, and cognitive status.
DESIGN: Multicenter cohort study with follow-up of up to
14 years.
SETTING: Patients from the two Multicenter Study of
Predictors of Disease Course in Alzheimer’s Disease (Pre-
dictors Study) cohorts were recruited at five sites in the
United States and Europe.
PARTICIPANTS: Patients diagnosed with probable AD
(n5536) enrolled in a longitudinal study (Predictors Study).
MEASUREMENTS: Depressive symptoms were evaluated
at 6-month intervals using the Columbia Scale for Psycho-
pathology in Alzheimer’s Disease. The Modified Mini-
Mental State (3MS) and Blessed Dementia Rating Scale
(BDRS) were used to assess cognitive status and functional
activity, respectively.
RESULTS: The prevalence of depressive symptoms was
stable over the first 3 years of follow-up, at approximately
40%. There was a significant drop to 28% and 24% in the
fourth and fifth years of follow-up, respectively. Time-de-
pendent Cox analysis revealed that functional activity
(BDRS) but not cognitive status (3MS) was a significant
predictor of the first episode of depressive symptoms during
follow-up. Generalized estimating equation analyses
showed that AD duration and functional activity but not
cognitive status were significantly related to depressive
symptoms over the entire follow-up period.
CONCLUSION: Depressive symptoms are common in
AD, but their prevalence decreases over time. Examina-
tion of the temporal relationship between depressive symp-
toms and risk factors suggests that decline in function but
not in cognition precedes the first episode of depressive
symptoms in patients with probable AD. J Am Geriatr Soc
53:2083–2089, 2005.
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Depression is common in Alzheimer’s disease (AD). Es-timates of the prevalence of depressive symptoms
cluster around 30% to 50%, although some estimates are as
low as 1%.1 This variability is likely attributable to several
factors, including different methods by which depression
was diagnosed,2–4 differences in study populations,5–8 and
whether the information was elicited from patients or from
significant others.9
Several studies have demonstrated that depressive
symptoms are persistent in AD,10–12 tend to occur early in
the disease,13–15 and decrease over time,16 but reliable risk
factors for depression, beyond previous episodes, have yet
to be identified in prospective research. This may be, at least
in part, attributed to the limited number of published pro-
spective studies that were designed to assess this matter
directly.
If depression in AD is uniquely related to disease
course, then the relationship between depression and dis-
ease-severity indices, such as functional activity and cogni-
tion, should be examined. Although the relationship
between cognitive status and psychopathology has been es-
tablished,10,17 the association between cognition and de-
pressive symptoms in AD remains equivocal. Studies have
suggested that depressive symptoms are related to less-
severe cognitive dysfunction13,18 as well as to more-severe
cognitive dysfunction,10,19,20 but several studies have found
that depressive symptomatology in AD is not related to
cognitive status.11,12,21–24 A cross-sectional study using a
large cohort suggested that depression was related to higher
cognitive status but lower functional activity.25 Finally,
there appears to be a consensus that lower functional ac-
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tivity at baseline is related to depression,12,26–28 although
the temporal relationship between depressive symptoms
and risk factors such as functional activity and cognition
has yet to be determined.
The present study was designed to characterize the
natural course of depressive symptoms in a large sample of
patients diagnosed with probable AD who were followed
prospectively for up to 14 years. Furthermore, whether
functional activity, cognitive status, and disease duration
were important predictors of depressive symptoms in AD
was examined. Two separate matters were addressed. First,
the temporal relationship between disease severity indices
and depressive symptoms was determined by examining
whether decline in function and cognition predicted the first
episode of depressive symptoms during the follow-up. Sec-
ond, whether the relationship between these disease-sever-
ity indices and the depressive symptoms was generalized
over the entire follow-up period was examined. To the au-
thors’ knowledge, this is the first study that provides such an
analysis of prospective data for patients with AD followed
from mild to severe stages of the disease.
Information regarding the natural course and risk fac-
tors of depression in AD is of significant value to clinicians
and caregivers of demented patients. There are several ex-
pert recommendations for the treatment of depression in
AD,29 but strong support for specific treatment recommen-
dations is absent (for review, see 1). Hence, knowledge re-
garding the natural course of depression and its relation to




A total of 536 patients enrolled in the Multicenter Study of
Predictors of Disease Course in Alzheimer’s Disease (Pre-
dictors Study) participated in the investigation. All patients
were diagnosed with probable AD.30,31 Patients from two
Predictors Study cohorts who were recruited at five separate
sites participated in the present study. In the United States,
patients from both cohorts were recruited at three sites:
Columbia Medical Center (n5205), Johns Hopkins School
of Medicine (n5142), and Massachusetts General Hospi-
tal (n5117). In the second cohort, two additional sites
were added: Hoˆpital de la Salpeˆtrie`re at Paris, France
(n5 38), and the University of Thessaly at Larissa, Greece
(n5 34). The inclusion/exclusion criteria and evaluation
procedures of the Predictors Study have been fully described
elsewhere.32,33 With respect to psychiatric history, exclu-
sion criteria included a history of schizophrenia or schizo-
affective disorder, electroconvulsive therapy within the
preceding 2 years or a history of 10 or more electroconvul-
sive treatments in any one course, alcohol or drug depend-
ence during the preceding 5 years, primary affective
disorder within 1 year before onset of dementia, and evi-
dence of other causes of dementia. At the Columbia site,
patients were recruited from the Memory Disorder Center
and from doctors’ private offices through the Alzheimer’s
Disease Research Center. Each consecutive patient who met
the inclusion/exclusion criteria of the study was included,
with the exception of those who did not consent to partic-
ipate or who lived too far away and were unable to return to
the hospital for regular follow-up. At the Johns Hopkins
site, patients were recruited from the Dementia Research
Center and from private physicians. For the Massachusetts
General Hospital site, patients were recruited from the
Geriatric Neurobehavioral Center, an outpatient service.
Patients at Hoˆpital de la Salpeˆtrie`re at Paris and at the Uni-
versity of Thessaly at Larissa were recruited from outpa-
tient clinics as well.
In the Predictors Study, patients are evaluated every
6 months. The mean number of semiannual visits  stand-
ard deviation for the entire sample was 5.6  5.5, with a
maximum of 28 visits, indicating that some of the patients
had been followed for up to 14 years. Attrition is low in the
Predictors Study. Follow-up was complete for 94.5% of the
two cohorts; only 5.5% had missing follow-up information
for the period of the last year before the most updated data
entry. The total number of patients followed each year from
the initial evaluation through the fifth year was 536, 460,
335, 243, 171, and 130, respectively. Of the 406 patients
who did not have the complete 5-year follow-up, 248 had
died. The remaining 158 patients were mostly subjects from
the second cohort at the U.S. and European sites who were
enrolled in the Predictors Study but whose follow-up was
shorter than 5 years. Patients’ cognitive status, functional
competence, and depression were evaluated at entry to the
study and at 6-month intervals thereafter. Given the tran-
sient nature of depressive symptoms in AD, it is possible
that not all depressive episodes (i.e., depression that was
shorter than 6 months) were captured in the analyses re-
ported in the present investigation. The percentage of pa-
tients who were on antidepressant medications each year
from the initial evaluation through the fifth year was 19%,
21%, 20%, 18%, 24%, and 21%, respectively.
Measures
Depressive symptoms
Depressive symptoms were assessed using the Columbia
University Scale for Psychopathology in Alzheimer’s Dis-
ease (CUSPAD).20 The CUSPAD is a short, semistructured
rating scale that clinicians or research technicians can ad-
minister to an informant. The frame of inquiry is the month
before examination. Most items are scored dichotomously
(i.e., symptom is present or absent). Psychometric proper-
ties of this instrument have been reported.20 Interrater re-
liability for the major symptom categories was established
for concurrent rating of a single interview (k50.74–1.00)
and for separate interviews (k50.53–0.73). Specifically
with respect to depression, interrater reliability was con-
sistent for separate (k50.73) and concurrent (k50.80)
rating of a single interview. A trained research technician
administered the CUSPAD to an informant at the initial
evaluation and at subsequent 6-month intervals. For the
purpose of the present study, three indices of depressive
symptoms were used. The first dichotomous index, which
was exclusive of physical symptoms of depression, deter-
mined whether the patient was sad. The second index used
a five-level scale to determine the extent and frequency
of depression exclusive of physical symptoms. The third
continuous index included physical symptoms (sleep and
appetite) that are often but not necessarily associated with
depression. Although the validity of the CUSPAD has been
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established, this instrument is not designed to diagnose or
discriminate between different depressive disorders per the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision, classification system.
Cognition
Cognition was assessed using the modified version of the
Mini-Mental State Examination (3MS).34,35 The 3MS was
administered in English at the U.S. sites and in French and
Greek translated versions in Paris and Larissa, respectively.
U.S. presidents, recall, and general knowledge items were
replaced with suitable French and Greek figures in the
French and Greek samples. Modifications to the original
3MS include the addition of Digit Span Forward and Back-
ward,36 two additional calculation items, recall of the cur-
rent and four previous presidents of the United States,
confrontation naming of 10 items from the Boston Naming
Test,37 one additional sentence to repeat, and one addi-
tional figure to copy. The 3MS has a maximum of 57 points,
with lower scores indicating poorer cognitive function.
Functional Dependence
Functional activity was assessed using the Blessed Dementia
Rating Scale (BDRS) Parts I and II.38 The range is between
0 and 17, with higher scores indicating greater functional
dependence.
General Health Status
Health status was calculated using the modified Charlson
Comorbidity Index.39 The following conditions were eval-
uated: peripheral vascular status, chronic renal disease,
systemic malignancy, hypertension, diabetes mellitus, con-
gestive heart failure, myocardial infarction, chronic ob-
structive pulmonary disease, chronic liver disease, and
abnormality of the abdomen and joints.
Statistical Analyses
Descriptive Statistics
Descriptive information, including the number of patients
followed, demographic characteristics, general health
(modified Charlson Comorbidity Index39), number of 6-
month visits, 3MS, BDRS, and depression evaluations, were
tabulated. The percentage of patients per year experiencing
depressive symptoms was reported for a 5-year period and
delineated in relation to yearly mean 3MS and BDRS
scores.
Time-Dependent Cox Analyses
Time-dependent Cox analysis was used to evaluate risk
factors that predicted the first episode of depressive symp-
toms during the follow-up period. Duration (in 6-month
blocks) between the initial visit and development of the
outcome or last evaluation without the outcome served as
the timing variable in each model. Cognitive status (3MS)
and functional activity (BDRS) served as time-dependent
covariates. Age, sex, education, cohort, antidepressant
medications use (at any point during the follow-up), and
modified Charlson Comorbidity Index39 served as fixed co-
variates. The dichotomous index of depressive symptoms
(exclusive of physical symptoms) from the CUSPAD served
as the dependent measure. The time-dependent Cox
analysis was used to accomplish two related objectives:
determine whether changes over time in function and
cognition predicted the first episode of depressive symptoms
during the follow-up, and establish the directionality
of the relationship between the time-dependent co-
variates and depression. To address this second objective,
a secondary analysis was performed on a subsample
of patients who had no history of depression before
the follow-up and who were not depressed at the baseline
evaluation.
General Estimating Equations
General estimating equations (GEEs) were used to evaluate
the relationship between the risk factors and depression
using the entire sample (n5536) over all available patient
visits. This statistical method takes into account the mul-
tiple visits per patient as well as the likelihood that an in-
dividual’s characteristics correlate with each other over
time. The repeated measures per patient (up to 28 6-month
visits) are treated as a cluster. A second advantage of GEE is
that it takes into account the status or changing value of
each covariate at each visit. Separate GEE models were run
for the three depression indices. Cognitive status (3MS),
functional activity (BDRS), and disease duration (time of
follow-up) served as predictors. Analyses controlled for
time, age, education, sex, antidepressant medication use,
Charlson Comorbidity Index, and cohort.
RESULTS
Sample characteristics at baseline (N5536) are summa-
rized in Table 1.
Of the 536 participants, 59% were female, and the ma-
jority were white. Mean age was 74.0  8.7; mean educa-
tion was 13.0  4.1 years, respectively. Mean baseline 3MS
was 38.2  6.1, indicating an overall mild level of cognitive
impairment; mean baseline BDRS score was 3.7  2.4,
indicating mild level of functional impairments.40
Table 1. Demographic Characteristics of the Sample
(N5536) at Baseline and Follow-Up Information
Characteristic Value N
Age, mean  SD 74  8.7
Education, years, mean  SD 13  4.1
3MS score, mean  SD 38.2  6.1
Blessed score, mean  SD 37.5  23.5
Charlson index, mean  SD 0.48  0.82
Illness duration, years, mean  SD 4.06  2.30
Female, % 59
Depressed, % 39.2
Cohort 1, % 45
6-month follow-up visits, mean  SD 5.6  5.5 4,142
Depression evaluations, mean  SD 5.43  5.4 3,557
Function (Blessed) evaluations,
mean  SD
5.45  5.4 3,592
Cognitive (3MS) evaluations,
mean  SD
4.0  3.9 2,940
Duration of illness from onset to baseline visit per neurologist’s estimate.
SD5 standard deviation; 3MS5modified Mini-Mental State Examination.
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Descriptive Statistics
The percentage of depressed patients in each of the 5 years
of follow-up is presented in Figure 1. These findings are
presented in relation to yearly mean 3MS and BDRS scores.
Figure 1 reveals that depressive symptoms were com-
mon and relatively stable during the first 3 years of the
follow-up, ranging from 40% to 42% of the sample. A
decrease in the prevalence of depressive symptoms to 28%
and 24% of the sample was observed in the fourth and fifth
years of follow-up, respectively. As expected, yearly mean
3MS scores decreased over time, indicating reduced cogni-
tive function. BDRS scores increased during the follow-up,
indicating a decline in functional activity. Prevalence rate of
depressive symptoms in a subset of patients who had com-
pleted 5 years of follow-up (n5 130) was similar. The per-
centage of patients in this subsample deemed depressed
each year in the initial evaluation through the fifth year was
39%, 43%, 42%, 40%, 30%, and 29%, respectively.
Hence, it is unlikely that attrition biased the results. Some
(but statistically insignificant, as judged using chi-square
analysis) variability at baseline was noted between the dif-
ferent sites in the prevalence rates of depressive symptoms:
Columbia (44%), Johns Hopkins (36%), Massachusetts
General Hospital (44%), Hoˆpital de la Salpeˆtrie`re (21%),
and University of Thessaly (33%).
Time-Dependent Cox Analysis
Time-dependent Cox analysis examined risk factors of the
first episode of depressive symptoms during the follow-up
period using 3MS and BDRS as the time-dependent covari-
ates. The results revealed that lower functional activity
(BDRS) but not cognitive status (3MS) was a significant
predictor of depression. Table 2 summarizes the results of
the time-dependent Cox analysis.
A second time-dependent Cox analysis was performed
on a subset of patients who reported no history of psycho-
pathology before their enrollment in the Predictors Study
and who were not depressed at baseline (n5 235). This
secondary analysis was designed to provide evidence with
respect to the directionality of the relationship between the
time-dependent covariates and first episode of depressive
symptoms. Consistent with the previous analysis, the results
showed that decline in function but not cognition predicted
the first episode of depressive symptoms during the follow-
up period (Table 2, Model 2).
GEE Analyses
Separate GEE analyses were performed on three CUSPAD
depression indices, with 3MS, BDRS, and time serving
as the predictors. Analyses controlled for time, age, sex,
education, cohort, heath status, and antidepressant medi-
















Figure 1. Percentage of patients deemed depressed at baseline
through the fifth year of follow-up in relation to yearly mean
modified Mini-Mental State Examination (3MS) and Blessed
Dementia Rating Scale (BDRS) total scores.
Table 2. Time-Dependent Cox Analyses: Prediction of First Episode of Depression
Variable
Model 1 Model 2w
Risk Ratio (95% Confidence Interval) P-value
Sex 1.07 (0.86–1.32) .56 1.17 (0.80–1.73) .42
Age 0.99 (0.98–1.00) .10 0.98 (0.96–1.01) .12
Education 0.98 (0.95–1.01) .12 1.02 (0.96–1.08) .50
Cohort 0.95 (0.76–1.18) .62 1.08 (0.71–1.64) .71
Antidepressant medications 1.36 (1.09–1.66) .006 1.44 (0.96–2.15) .08
Charlson index 1.05 (0.95–1.16) .34 1.17 (0.79–1.72) .43
Modified Mini-Mental State Examinationz 1.01 (1.00–1.02) .13 1.01 (0.99–1.04) .26
Blessed Dementia Rating Scalez 1.01 (1.00–1.01) o.001 1.01 (1.00–1.02) .003
Entire sample.
w Subset of patients (n5235) with no history of psychopathology (including depression) before enrollment in the Predictors Study and who were not depressed at
baseline.
zTime-dependent covariates.
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cation use. Results of the analyses are summarized in
Table 3.
Consistent with the descriptive data, time was nega-
tively associated with depression in all three models. (The
prevalence of depression decreased over time.) BDRS scores
were significant predictors of depression in all three models,
indicating that decline in functional activity was related to
increased depression. In contrast, 3MS scores were not sig-
nificant predictors of depression in two of the three models.
The relationship between 3MS and depression was statis-
tically significant in Model 1. These findings are consistent
with the time-dependent Cox analysis demonstrating that,
although decline in functional activity was related to de-
pression, cognitive function was not a reliable predictor
of depressive symptoms in AD.
DISCUSSION
The present study examined the natural course and prev-
alence of depressive symptoms in a large cohort of patients
diagnosed with probable AD, followed longitudinally for
up to 14 years. Risk factors for depression were identified.
Specifically, whether functional activity, cognitive status,
and time were related to the risk of experiencing depressive
symptoms was evaluated.
The prevalence of depressive symptoms was stable at
approximately 40% during the first 3 years of follow-up,
with a significant drop in the fourth and fifth years of fol-
low-up. These findings are consistent with previous studies
indicating that depression is common in the early phase of
the disease13–15 and then decreases over time.16 These re-
sults may explain some of the reported variability of de-
pressive symptoms in AD, because the prevalence rates
varied substantially as a function of time and disease course.
It should be emphasized that changes in prevalence of de-
pression over the course of follow-up are not likely to reflect
fluctuations in the number of patients evaluated each year.
Indeed, such prevalence rates were similar in a subset of
patients who were assessed at every 6-month evaluation
during the 5-year follow-up. Furthermore, the negative ef-
fect of time on depression, which was evident in all three
GEE models, substantiated the descriptive data in demon-
strating that the prevalence of depression declined over
time. The possibility cannot be excluded that compromised
communication in the later phases of AD41 may have lim-
ited the ability to assess depression, but given the variability
in communication skills observed in the advanced stages of
the disease,42 it is unlikely that the drop in prevalence of
depressive symptoms in the fourth and fifth years of follow-
up can be attributed exclusively to patients’ inability to
communicate that they were depressed.
The findings of this investigation extend previous re-
search in supporting an association between function and
depression in AD.12,25–28 Decline in function predicted the
first episode of depressive symptoms during the follow-up
period and was associated with greater risk of depression
when taking into account all patient visits. This association
remained reliable even after controlling for the effects of a
large number of variables that could have attenuated the
relationship between depression and functional activity.
Moreover, the present study was designed to evaluate
the temporal relationship between functional activity and
depression. Lower functional activity may precede or fol-
low the onset of depressive symptoms. The time-dependent
Cox analysis provided the most convincing evidence in sup-
port of the former interpretation. Changes over time in
functional activity served as a time-dependent covariate,
which predicted the first episode of depressive symptoms
during the follow-up period. The direction of this relation-
ship was further demonstrated in a subset of patients who
reported no history of psychopathology (inclusive of de-
pression) before being diagnosed with probable AD and who
were not depressed at baseline. Hence, the possibility that
premorbid history of psychopathology might confound these
findings does not appear to be supported in this sample.
Determining the direction of the relationship between
functional activity and depression is important inasmuch
as it has implications for the etiology and treatment of
Table 3. General Estimating Equation (GEE) Analyses: Prediction of Three Separate Depression Indices Across All
Available Visits
Variable
Model 1 Model 2w Model 3z
b (95% Confidence Interval) P-value
Sex 0.002 ( 0.061–0.066) .95  0.038 ( 0.167–0.092) .57  0.167 ( 0.413–0.080) .19
Age  0.003 ( 0.007–0.001) .14 0.000 ( 0.008–0.008) .97  0.016 ( 0.031–0.001) .03
Education 0.000 ( 0.009–0.008) .95  0.005 ( 0.022–0.012) .56  0.028 ( 0.062–0.005) .10
Antidepressant
medications
0.049 ( 0.015–0.113) .14 0.127 ( 0.016–0.271) .08  0.205 ( 0.057–0.466) .13
Charlson index 0.016 ( 0.019–0.042) .46  0.010 ( 0.049–0.069) .74  0.056 ( 0.055–0.167) .32
Cohort  0.015 ( 0.083–0.052) .66  0.062 ( 0.200–0.075) .37  0.167 ( 0.109–0.442) .24
Time  0.022 ( 0.037–0.007) .004  0.064 ( 0.092–0.037) o.001  0.220 ( 0.276–0.156) o.001
Modified Mini-Mental
State Examination
0.003 (0.000–0.006) .03  0.005 ( 0.001–0.011) .11  0.007 ( 0.005–0.019) .26
Blessed Dementia
Rating Scale
0.002 (0.001–0.002) o.001  0.003 (0.001–0.005) o.001 0.013 (0.009–0.017) o.001
Depression is dichotomous exclusive of physical symptoms.
wFrequency of depression exclusive of physical symptoms.
zTotal depression scores inclusive of physical symptoms.
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depression in AD. A few recent studies suggest that the
combination of cognitive rehabilitation and pharmacolog-
ical intervention may result in some improvement in cog-
nitive status and functional activity43–45 in patients with
AD. In this context of rehabilitative treatment, one possible
implication is that structuring the patient’s environment to
maximize independence or possibly even the perception of
independence may help to reduce the extent of depressive
symptoms.
In contrast to functional activity, cognitive function
was not a significant predictor of first episode of depression
during the follow-up, nor was it reliably related to depres-
sion when taking into account all available patient visits.
Although the lack of association between cognitive function
and depression in AD has been reported in other studies,21
two related indices of AD severity (3MS and BDRS) are dif-
ferentially related to the risk of experiencing depression
during the course of the disease. Moreover, a previous study
revealed that subjective memory complaints were unrelated
to depressive symptoms in preclinical AD.14 Taking these
together, it appears that, whereas cognitive decline or the
perception of reduced cognitive capacity are not related to
depression, the practical consequences of having the disease,
which results in loss of independence (i.e., function), are
consistently related to increased risk of depression in AD.
A limitation of the present study is the assessment of
depression. Although the CUSPAD has been validated for
use in AD,20 it was developed primarily to examine phen-
omenological features. Consequently, partial response to
treatment and fluctuation over time in symptom severity
may not be detected with this instrument. Nonetheless, an
attempt was made to address this limitation by deriving a
second depression index that was sensitive to the frequency
of depressive symptoms. A third index of depression inclu-
sive of physical symptoms was derived as well. The rela-
tionship between depression and functional activity was
demonstrated in all analyses in this paper irrespective of
how depression was assessed. This suggests that the findings
are likely not attributable to the method by which depres-
sion was evaluated. This study relied on informant reports
to assess patients’ depressive symptoms. Whereas patients
tend to underreport symptoms, informant variables, such as
perceived burden, may be related to greater reporting of
depressive symptoms in patients. Hence, it cannot be ex-
cluded that informants’ variables may have partially influ-
enced the results as well. Another limitation is the
assessment of the antidepressant medications. Although
all analyses controlled for the effect of a large range of
antidepressant medications, this study was not designed to
monitor therapeutic aspects such as medication type and
dosage and adherence to the prescribed treatment. Conse-
quently, and despite the stringent control over the possible
effect of antidepressant medications on the findings, it is
possible that this study underestimated the effect of phar-
macological intervention on depressive symptoms in AD.
The longitudinal design of this study has significant
advantages over cross-sectional studies and prospective
studies of short follow-up when evaluating the manifesta-
tion of depression over time and in relation to functional
and cognitive status in AD. Specifically, when assessed lon-
gitudinally, changes in depressive symptoms can be attrib-
uted directly to disease progress and to the decline in
functional activity. In contrast, findings from cross-section-
al studies and short follow-up prospective studies cannot be
used to make inferences regarding such disease processes.
(For a recent review concerning the limitations of cross-
sectional studies with respect to disease processes see 46.)
Further confidence in the finding of the present study is
attributed to the careful diagnosis and follow-up that the
patients received and the high confirmation rate of AD in
autopsy cases.47,48 The assessment of functional activity,
cognitive status, and depression relies on standardized
measures that have been validated in patients with AD and
on uniform application of widely accepted criteria in a
consensus diagnostic conference procedure. The semiannu-
al evaluations conducted throughout the follow-up period
increase the diagnostic reliability and validity of emotional,
cognitive, and functional status. Finally, because the par-
ticipants in this study were recruited from two separate
cohorts and five different centers in the United States and
Europe, the findings reported in the investigation are likely
to generalize to patients seen in memory disorder clinics and
AD centers in hospitals. Generalizability to community-
based samples will have to be addressed in future research.
In summary, this study delineated the natural course of
depression in AD and evaluated the possible relationship
between three disease indices and depressive symptoms.
Whereas functional activity and the time of follow-up were
reliable predictors of depression, cognitive function was
not. Furthermore, the findings suggest that decline in func-
tional activity precedes the onset of depressive symptoms in
AD. Future research should directly examine whether, in the
context of rehabilitative treatment, increasing patients’ lev-
el or perception of independence reduces depressive symp-
toms in AD.
ACKNOWLEDGMENTS
Financial Disclosure: R. Holtzer, N. Scrameas, D. Wegesin,
J. Brandt, M. Albert, B. Dubois, and M. Hadjigeorgiou in-
dicate no financial disclosures. Y. Stern is a consultant for
Eisai Pharmaceuticals and Cortex Pharmaceuticals.
Author Contributions: R. Holtzer, N. Scrameas, and Y.
Stern: concept, design, analysis and interpretation of data,
manuscript preparation. D. Wegesin, J. Brandt, M. Albert,
B. Dubois, and G.M. Hadjigeorgiou: acquisition of subjects
and data, manuscript preparation.
Sponsor’s Role: None.
REFERENCES
1. Olin JT, Katz IR, Meyers BS et al. Provisional diagnostic criteria for depression
of Alzheimer disease. Am J Geriatr Psychiatry 2002;10:129–141.
2. Regier DA. Limitations of diagnostic criteria and assessment instruments for
mental disorders. Arch Gen Psychiatry 2000;57:109–115.
3. Eaton WW, Neufeld K, Chen LS et al. A comparison of self-report and clinical
diagnostic interviews for depression. Arch Gen Psychiatry 2000;57:217–222.
4. Murphy JM, Monson RR, Laird N et al. A comparison of diagnostic interview
for depression in the Stirling County Study. Arch Gen Psychiatry 2000;57:230–
236.
5. Harwood DG, Barker WW, Ownby RL. Depressive symptoms in Alzheimer’s
disease: An examination among community dwelling Cuban American
patients. Am J Geriatr Psychiatry 2000;8:84–91.
6. Harwood DG, Barker WW, Ownby RL. Clinical characteristics of community-
dwelling black Alzheimer’s disease patients. J Natl Med Assoc 2005;92:
424–429.
7. Liu CY, Fu JL, Teng EL. Depressive disorders in Chinese patients with
Alzheimer’s disease. Acta Psychiatr Scand 1999;100:451–455.
2088 HOLTZER ET AL. DECEMBER 2005–VOL. 53, NO. 12 JAGS
8. Skoog I. The prevalence of psychotic, depressive and anxiety syndromes in
demented and non-demented 85-year-olds. Int J Geriatr Psychiatry 1993;
8:247–253.
9. Mackenzie TB, Robiner WN, Knopman DS. Differences between patient and
family assessments of depression in Alzheimer’s disease. Am J Psychiatry 1989;
146:1174–1178.
10. Devanand D, Jacobs DM, Tang MX et al. The course of psychopathology in
mild to moderate Alzheimer’s disease. Arch Gen Psychiatry 1997;54:257–263.
11. Levy ML, Cummings JL, Fairbanks LA et al. Longitudinal assessment of
symptoms of depression, agitation, and psychosis in 181 patients with Alz-
heimer’s disease. Am J Psychiatry 1996;153:1438–1443.
12. Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J et al. Evolution of depressive
symptoms in Alzheimer’s disease: One year follow-up. Alzheimer Dis Assoc
Disord 2003;17:77–85.
13. Zubenko GS, Zubenko WN, McPherson S. A collaborative study of the emer-
gence and clinical features of the major depressive syndrome in Alzheimer’s
disease. Am J Psychiatary 2003;160:857–866.
14. Berger AK, Fratiglioni I, Forsell Y et al. The occurrence of depressive symp-
toms in the preclinical phase of AD. A population-based study. Neurology
1999;53:1998–2002.
15. Chen P, Ganguli M, Mulsant BH et al. The temporal relationship between de-
pressive symptoms and dementia. Arch Gen Psychiatry 1999;56:261–266.
16. Li YS, Meyer JS, Thornby J. Longitudinal follow-up of depressive symptoms
among normal versus cognitively impaired elderly. Int J Geriatr Psychiatry
2001;16:718–727.
17. Holtzer R, Tang M-X, Devanand D et al. Psychopathological features in Alz-
heimer’s disease: Course and relationship with cognitive status. J Am Geriatr
Soc 2003;51:953–960.
18. Lopez OL, Boller F, Becker TL. Alzheimer’s disease and depression: Neuro-
psychological impairment and progression of the illness. Am J Psychiatry
1990;147:855–860.
19. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. Br
J Psychiatry 1990;157:72–76.
20. Devanand DP, Miller L, Richards M et al. The Columbia University Scale for
Psychopathology in Alzheimer’s disease. Arch Neurol 1992;49:371–376.
21. Ballard C, Bannister C, Solis M et al. The prevalence, associations and symptoms
of depression amongst dementia sufferers. J Affect Disord 1996;36:135–144.
22. Cooper JK, Mungas D, Weiler P. Relation of cognitive status and abnormal
behaviors in Alzheimer’s disease. J Am Geriatr Soc 1990;38:867–870.
23. Cummings JL, Miller B, Hill MA et al. Neuropsychiatric aspects of multi-
infract dementia and dementia of the Alzheimer type. Arch Neurol 1987;
44:389–393.
24. Lazarus LW, Newton N, Cohler B et al. Frequency and presentation of de-
pressive symptoms in patients with primary degenerative dementia. Am J Psy-
chiatry 1987;144:41–45.
25. Payne JL, Lyketsos CG, Steele C et al. Relationship of cognitive and functional
impairment to depressive features in Alzheimer’s disease and other dementias.
J Neuropsychiatry Clin Neurosci 1998;10:440–447.
26. Lyketsos CG, Steele C, Baker L et al. Major and minor depression in Alz-
heimer’s disease: Prevalence and impact. J Neuropsychiatry Clin Neurosci
1997;9:556–561.
27. Pearson JL, Teri L, Reifler BVet al. Functional status and cognitive impairment
in Alzheimer patients with and without depression. J Am Geriatr Soc 1989;37:
1117–1121.
28. Fits AG, Teri L. Depression cognition and functional ability in patients with
Alzheimer’s disease. J Am Geriatr Soc 1994;42:186–191.
29. Lyketsos CGI, Campo L, Steinberg M et al. Treating depression in Alzheimer
disease: Efficacy and safety of sertraline therapy and the benefits of depression
reduction: The DIADS. Arch Gen Psychiatry 2003;60:737–746.
30. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s
disease. Report of the NINCDS-ADRDA Work Group under the auspices of
the Department of Health and Human Services Task Force on Alzheimer’s
disease. Neurology 1984;34:939–944.
31. Diagnostic and Statistical Manual of Mental Disorders, Revised, 3rd Ed.
Washington, DC: American Psychiatric Press, Inc., 1987.
32. Stern Y, Albert SM, Sano M et al. Assessing patient dependence in Alzheimer’s
disease. J Gerontol 1994;49:M216–M222.
33. Richards M, Folstein M, Albert M et al. Multi-center study of predictors of
disease course in Alzheimer’s disease (the ‘Predictors Study’). II. Baseline find-
ings. Alzheimer Dis Assoc Disord 1993;7:22–32.
34. Stern Y, Sano M, Paulson J et al. Modified Mini-Mental State Examination.
Validity and reliability. Neurology 1987;37:179.
35. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method
for grading the cognitive state of patients for the clinician. J Psychiatr Res
1975;12:189–198.
36. Wechsler D. Wechsler Adult Intelligence ScaleFRevised. New York: The Psy-
chological Corporation, 1981.
37. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders,
2nd Ed. Philadelphia: Lea & Febiger, 1983.
38. Blessed G, Tomlinson BE, Roth M. The association between quantitative
measures of senile change in the cerebral grey matter of elderly subjects. Br
J Psychol 1968;114:797–811.
39. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic
comorbidity in longitudinal studies: Development and validation. J Chronic
Dis 1987;40:373–383.
40. Eastwood MR, Lautenschlaeger E, Corbin S. A comparison of clinical meth-
ods for assessing dementia. J Am Geriatr Soc 1983;31:342–347.
41. Ripich DN, Fritsch T, Ziol E et al. Compensatory strategies in picture de-
scription across severity levels in Alzheimer’s disease: A longitudinal study. Am
J Alzheimer Dis 2000;15:217–228.
42. Bayles KA, Tomoeda CK, Cruz RF et al. Communication abilities of individ-
uals with late-stage Alzheimer disease. Alzheimer Dis Assoc Disord 2000;
14:176–181.
43. Loewenstein DA, Acevedo A, Czaja SJ et al. Cognitive rehabilitation of mildly
impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr
Psychiatry 2004;12:395–402.
44. Rogers JC. Understanding Alzheimer disease: From diagnosis to rehabilitation.
Phys Occup Ther Geriatr 2002;20:103–123.
45. Bottino C, Carvalho I, Alvarez AM et al. Cognitive rehabilitation in Alz-
heimer’s patients: Multidisciplinary team report. Arq Neuropsiquiatr 2002;
60:70–79.
46. Kraemer HC, Yesavage JA, Taylor A et al. How can we learn about devel-
opmental processes from cross-sectional studies, or can we? Am J Psychiatry
2000;157:163–179.
47. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A et al. Motor signs during
the course of Alzheimer’s disease. Neurology 2004;63:975–982.
48. Scarmeas N, Albert M, Brandt J et al. Motor signs predict poor outcomes in
Alzheimer disease. Neurology 2005;64:1696–1703.
DEPRESSIVE SYMPTOMS IN AD 2089JAGS DECEMBER 2005–VOL. 53, NO. 12
